LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Aligns Liora and the LiGHT System With LB-100 to Push the Frontier of Cancer Treatment
-LIXTE Biotechnology recently acquired Liora Technologies, and the acquisition includes Liora’s proprietary LiGHT system
- This system provides several advantages over technologies that are currently available for treating tumors with proton therapy
- The LiGHT system also complements LIXTE’s LB-100, which is the company’s lead clinical candidate that’s designed to help boost the activity of both chemotherapy and immunotherapy
LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, recently acquired Liora Technologies, a company that’s pioneering proton therapy systems for treating tumors in various types of cancers.
Liora is becoming a wholly owned subsidiary of LIXTE, and the acquisition also includes Liora’s proprietary flagship technology, the LiGHT System (Linac for Image Guided Hadron Therapy), which offers many advantages over other technologies that are currently available for treating tumors with proton therapy.
According to Professor Steve Myers, the former Director of Accelerators and Technology at CERN (European Organization for Nuclear Research): “The highly adaptable LiGHT System provides a proton beam allowing the delivery of very high dose rates to deep-seated tumors. In addition to the unique biological effects, it will also greatly reduce the installation cost and the number of treatment sessions needed, compared to current technologies, and is expected to significantly increase the number of patients that a treatment center can serve. “
Liora’s LiGHT System is installed at the Science and Technology Facilities Council’s (“STFC”) Daresbury Laboratory, where it has already achieved 230 MeV proton beam energy, a critical validation milestone that places the platform on par with, and potentially ahead of, incumbent proton therapy systems.
Speaking about the acquisition of Liora, LIXTE CEO Geordan Pursglove said that “The acquisition of Liora represents our entry in the radiotherapy segment of cancer care and marks a significant step in LIXTE’s corporate growth and development as we aim to fulfill our mission of treating cancer with cutting-edge technologies.” He also added that “We believe that Liora’s flagship technology LiGHT System has significant global potential and could well set a new gold standard in cancer care, delivering high-precision proton therapy that is scalable and clinically versatile.”
Pursglove also states that the addition of Liora represents an excellent complement to the pharmaceutical side of the business, particularly LIXTE’s ongoing clinical trials with LB-100, the company’s lead clinical candidate. LiGHT’s ability to deliver higher, more precise radiation doses creates potential synergy with radiosensitizers while its software-controlled energy delivery enables personalized treatment, aligning well with combination-therapy strategies.
LB-100 is designed to enhance the activity of chemotherapy and immunotherapy and has demonstrated a favorable safety profile in Phase 1 clinical trials and is supported by over 25 preclinical and translational studies.
It’s currently being evaluated in multiple programs that are targeting solid tumors that only have limited treatment options.
The ongoing trials and studies are being done in collaboration with leading academic cancer centers and partners and include combining LB-100 with immunotherapy in ovarian clear cell carcinoma and metastatic MSI-low colon cancer, as well as combining it with chemotherapy in advanced soft tissue sarcoma.
About LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT)
LIXTE Biotechnology Holdings is a clinical-stage pharmaceutical company that’s developing cancer therapies. Rather than standalone treatments, the company focuses on advancing an approach to boost the effectiveness of established therapies and addressing challenges. Alongside internal development, the company has also taken strategic action to extend capabilities beyond developing drugs.
For more information, visit the company website at https://lixte.com.
NOTE TO INVESTORS: The latest news and updates relating to LIXT are available in the company’s newsroom at https://nnw.fm/LIXT
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
-LIXTE Biotechnology recently acquired Liora Technologies, and the acquisition includes Liora’s proprietary LiGHT system
- This system provides several advantages over technologies that are currently available for treating tumors with proton therapy
- The LiGHT system also complements LIXTE’s LB-100, which is the company’s lead clinical candidate that’s designed to help boost the activity of both chemotherapy and immunotherapy
LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, recently acquired Liora Technologies, a company that’s pioneering proton therapy systems for treating tumors in various types of cancers.
Liora is becoming a wholly owned subsidiary of LIXTE, and the acquisition also includes Liora’s proprietary flagship technology, the LiGHT System (Linac for Image Guided Hadron Therapy), which offers many advantages over other technologies that are currently available for treating tumors with proton therapy.
According to Professor Steve Myers, the former Director of Accelerators and Technology at CERN (European Organization for Nuclear Research): “The highly adaptable LiGHT System provides a proton beam allowing the delivery of very high dose rates to deep-seated tumors. In addition to the unique biological effects, it will also greatly reduce the installation cost and the number of treatment sessions needed, compared to current technologies, and is expected to significantly increase the number of patients that a treatment center can serve. “
Liora’s LiGHT System is installed at the Science and Technology Facilities Council’s (“STFC”) Daresbury Laboratory, where it has already achieved 230 MeV proton beam energy, a critical validation milestone that places the platform on par with, and potentially ahead of, incumbent proton therapy systems.
Speaking about the acquisition of Liora, LIXTE CEO Geordan Pursglove said that “The acquisition of Liora represents our entry in the radiotherapy segment of cancer care and marks a significant step in LIXTE’s corporate growth and development as we aim to fulfill our mission of treating cancer with cutting-edge technologies.” He also added that “We believe that Liora’s flagship technology LiGHT System has significant global potential and could well set a new gold standard in cancer care, delivering high-precision proton therapy that is scalable and clinically versatile.”
Pursglove also states that the addition of Liora represents an excellent complement to the pharmaceutical side of the business, particularly LIXTE’s ongoing clinical trials with LB-100, the company’s lead clinical candidate. LiGHT’s ability to deliver higher, more precise radiation doses creates potential synergy with radiosensitizers while its software-controlled energy delivery enables personalized treatment, aligning well with combination-therapy strategies.
LB-100 is designed to enhance the activity of chemotherapy and immunotherapy and has demonstrated a favorable safety profile in Phase 1 clinical trials and is supported by over 25 preclinical and translational studies.
It’s currently being evaluated in multiple programs that are targeting solid tumors that only have limited treatment options.
The ongoing trials and studies are being done in collaboration with leading academic cancer centers and partners and include combining LB-100 with immunotherapy in ovarian clear cell carcinoma and metastatic MSI-low colon cancer, as well as combining it with chemotherapy in advanced soft tissue sarcoma.
About LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT)
LIXTE Biotechnology Holdings is a clinical-stage pharmaceutical company that’s developing cancer therapies. Rather than standalone treatments, the company focuses on advancing an approach to boost the effectiveness of established therapies and addressing challenges. Alongside internal development, the company has also taken strategic action to extend capabilities beyond developing drugs.
For more information, visit the company website at https://lixte.com.
NOTE TO INVESTORS: The latest news and updates relating to LIXT are available in the company’s newsroom at https://nnw.fm/LIXT
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
